MBII: Marrone Bio Innovations adds to credit facility based on short term assets. Our estimates do not include any financials from the recent acquisitions.HomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets open in 9 hrs 23 minsS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)MBII: Marrone Bio Innovations adds to credit facility based on short term assets. Our estimates do not include any financials from the recent acquisitions.Zacks Small Cap ResearchJanuary 10, 2020ReblogShareTweetShareBy Ian Gilson, PhD, CFANASDAQ:MBIIREAD THE FULL MBII RESEARCH REPORTMarrone Bio Innovations (NASDAQ:MBII) has increased its line of credit based on accounts receivable from $7 million to $20 million and has added a line of credit backed by its inventory. Both additional funds will be made available from LSQ Funding Group [https://lsq.com].Small high growth companies frequently our pace their cash as they try to balance cash/accounts receivable/inventories/accounts payable with operating expenses. This is especially difficult when revenue is highly seasonal and costs occur in different accounting periods than accounts receivable are paid.Lending organizations have a lot more access to the financials than do analysts so it is encouraging that LSQ Funding has such confidence in Marrone Bio Innovations to guarantee access to $18 million of additional funding.Our estimates do not include any data from the recent acquisitions since no current or historical data is available at this time. When the impact of the acquisitions becomes available we will adjust our forecasts accordingly.SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.  DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextTexas woman charged with stealing Rockets owner Tilman Fertitta's identity to buy furnitureYahoo SportsLenovo Has One Number That Deserves ScrutinyBloombergBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoCrocs CEO explains its major turnaroundYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoSome ISS (CPH:ISS) Shareholders Have Copped A Big 57% Share Price DropSimply Wall St.What the GM strike means for the U.S. economyYahoo FinanceWhy negative interest rates are 'seriously dangerous': strategistYahoo FinanceAurora Cannabis tumbles after double downgradeYahoo Finance VideoCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoWhy We’re Not Keen On YHI International Limited’s (SGX:BPF) 3.8% Return On CapitalSimply Wall St.Loan growth will be a 'critical factor' in upcoming bank earnings: AnalystYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo Finance